Robert A Philibert

US Patent:

6566061, May 20, 2003

Filed:

Jan 26, 2000

Appl. No.:

09/491356

Inventors:

Robert A. Philibert - Iowa City IA
Edward I. Ginns - Bethesda MD
Lynn Delisi - Stony Brook NY

Assignee:

The University of Iowa, as represented by the University of Iowa Research Foundation - Iowa City IA
The United States of America as represented by the Department of Health and Human Services - Washington DC

International Classification:

C07H 2104

US Classification:

435 6, 435 912, 536 231, 536 243, 536 2433

Abstract:

Nucleic acid sequences within the q13 region of the X chromosome having polymorphisms associated with neuropsychiatric disorders and associated conditions are disclosed herein. One polymorphism occurs within the coding region of the HOPA gene and introduces a four amino acid insertion into a putative OPA domain, a domain which has been shown to be involved in tissue specific expression. Compositions including nucleic acids having these polymorphisms and antibodies to polymorphic regions within proteins encoded in the PCTG4 region are provided. Methods of using the information and nucleic acid sequences disclosed herein for the diagnosis and assessment of pathologies associated with neuropsychiatric disorders and associated conditions are also provided.

US Patent:

8637652, Jan 28, 2014

Filed:

Oct 28, 2011

Appl. No.:

13/284425

Inventors:

Robert Philibert - Iowa City IA, US
Anup Madan - Bellevue WA, US

International Classification:

C07H 21/02
G01N 33/44

US Classification:

536 231, 436 94

Abstract:

The present invention provides screening kits, compositions, and diagnostic methods for determining whether a subject has a predisposition to, or likelihood of having, a substance use disorder by determining a nucleic acid methylation profile from a biological sample from the subject, wherein a given profile indicates that the subject has a predisposition to a substance use disorder.

US Patent:

20070248576, Oct 25, 2007

Filed:

Dec 22, 2006

Appl. No.:

11/644198

Inventors:

Robert Philibert - University Heights IA, US
Anup Madan - Bellevue WA, US

International Classification:

C12Q 1/68
C12N 5/00

US Classification:

424093700, 435325000, 435375000, 435006000, 536023100

Abstract:

Described herein is a CpG island in the 5′ region of the 5HTT gene that contains an alternative exon 1 and promoter for 5HTT. Methylation at this CpG island is associated with decreased levels of 5HTT mRNA, and this effect is evident when 5HTTLPR genotype is taken into account. Thus, this methylation status indicates 5HTT mRNA production, which serves as an indicator for the expression of the transporter and of a subject's vulnerability to diseases related to serotonergic activity. Accordingly, certain embodiments of the present invention provide diagnostic methods for determining whether a subject has, or is at risk for developing, a disease associated with serotonergic activity.

US Patent:

20070292880, Dec 20, 2007

Filed:

May 7, 2007

Appl. No.:

11/800629

Inventors:

Robert Philibert - University Heights IA, US
Anup Madan - Bellevue WA, US

International Classification:

C12Q 1/68
G01N 33/00

US Classification:

435006000, 436094000

Abstract:

The present invention provides screening kits, compositions, and diagnostic methods for determining whether a subject has a predisposition to, or likelihood of having, a substance use disorder or mental illness or syndrome by determining a nucleic acid expression profile from a biological sample from the subject, wherein a given profile indicates that the subject has a predisposition to a substance use disorder or mental illness or syndrome.

US Patent:

20110318735, Dec 29, 2011

Filed:

Apr 15, 2011

Appl. No.:

13/087993

Inventors:

Robert Philibert - Iowa City IA, US
Anup Madan - Iowa City IA, US

Assignee:

University of Iowa Research Foundation - Iowa City IA

International Classification:

C12Q 1/68

US Classification:

435 611

Abstract:

Described herein is a CpG island in the 5′ region of the 5HTT gene that contains an alternative exon 1 and promoter for 5HTT. Methylation at this CpG island is associated with decreased levels of 5HTT mRNA, and this effect is evident when 5HTTLPR genotype is taken into account. Thus, this methylation status indicates 5HTT mRNA production, which serves as an indicator for the expression of the transporter and of a subject's vulnerability to diseases related to serotonergic activity. Accordingly, certain embodiments of the present invention provide diagnostic methods for determining whether a subject has, or is at risk for developing, a disease associated with serotonergic activity.

US Patent:

20220220551, Jul 14, 2022

Filed:

Apr 22, 2020

Appl. No.:

17/605019

Inventors:

- Coralville IA, US
Robert Philibert - Iowa City IA, US

International Classification:

C12Q 1/6858
C12Q 1/6881

Abstract:

This disclosure relates to differentially methylated regions (DMRs) and an equation that can be applied when using epigenetic analysis in a biological sample that includes more than one cell type and, therefore, more than one methylation set point (e.g., saliva). This disclosure relates to differentially methylated regions (DMRs) and an equation that can be applied when using epigenetic analysis in a biological sample that includes more than one cell type and, therefore, more than one methylation set point (e.g., saliva).

US Patent:

20230041334, Feb 9, 2023

Filed:

Nov 13, 2020

Appl. No.:

17/776968

Inventors:

- Iowa City IA, US
Alejandro Comellas - Iowa City IA, US
Alicia GERKE - Iowa City IA, US
Robert PHILIBERT - Iowa City IA, US

Assignee:

BEHAVIORAL DIAGNOSTICS, LLC - Iowa City IA
UNIVERSITY OF IOWA RESEARCH FOUNDATION - Iowa City IA

International Classification:

A61K 31/519
A61K 31/4162
A61K 31/5375
A61K 31/352
A61P 25/34

Abstract:

This disclosure describes the use of a phosphodiesterase-5 (PDE5) inhibitor to reduce an individual's desire to smoke and/or frequency of smoking. In some embodiments, the PDE5 inhibitor is sildenafil (e.g., Viagra).

US Patent:

20230008544, Jan 12, 2023

Filed:

Jul 5, 2022

Appl. No.:

17/857723

Inventors:

- Iowa City IA, US
Robert Philibert - Iowa City IA, US

International Classification:

C12Q 1/6883

Abstract:

Methods and compositions are provided for detecting a predisposition for cardiovascular disease in an individual.